FY2029 Earnings Estimate for TSE:ONC Issued By HC Wainwright

Oncolytics Biotech Inc. (TSE:ONC) – Investment analysts at HC Wainwright issued their FY2029 earnings per share (EPS) estimates for shares of Oncolytics Biotech in a research report issued on Monday, February 3rd. HC Wainwright analyst P. Trucchio anticipates that the company will post earnings of $1.10 per share for the year. The consensus estimate for Oncolytics Biotech’s current full-year earnings is ($0.41) per share.

Oncolytics Biotech (TSE:ONC) last released its earnings results on Tuesday, November 12th. The company reported C($0.12) EPS for the quarter, missing the consensus estimate of C($0.11) by C($0.01). During the same period last year, the company earned ($0.14) earnings per share.

Separately, Raymond James upgraded Oncolytics Biotech to a “moderate buy” rating in a report on Thursday, November 14th.

Oncolytics Biotech Stock Down 5.6 %

ONC stock opened at C$1.01 on Tuesday. Oncolytics Biotech has a 1-year low of C$0.98 and a 1-year high of C$2.08. The business has a fifty day moving average price of C$1.24 and a 200-day moving average price of C$1.37. The company has a debt-to-equity ratio of 6.09, a current ratio of 4.99 and a quick ratio of 8.86. The stock has a market capitalization of C$77.63 million, a P/E ratio of -2.66 and a beta of 1.35.

About Oncolytics Biotech

Oncolytics Biotech Inc, a clinical-stage biopharmaceutical company, focuses on the discovery and development of pharmaceutical products for the treatment of cancer. The company is developing pelareorep, an intravenously delivered immunotherapeutic agent, which is in phase 3 clinical trial for the treatment of hormone receptor-positive / human epidermal growth factor 2-negative metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma.